Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

Reid W. Merryman; Nicole A. Carreau; Ranjana H. Advani; Michael A. Spinner; Alex F. Herrera; Robert Chen; Sarah Tomassetti; Radhakrishnan Ramchandren; Muhammad Hamid; Sarit Assouline; Raoul Santiago; Nina Wagner-Johnston; Suman Paul; Jakub Svoboda; Steven M. Bair; Stefan K. Barta; Yang Liu; Sunita Nathan; Reem Karmali; Madelyn Burkart; Pallawi Torka; Kevin A. David; Catherine Wei; Frederick Lansigan; Lukas Emery; Daniel Persky; Sonali M. Smith; James Godfrey; Julio Chavez; Jonathan B. Cohen; Andrea B. Troxel; Catherine Diefenbach; Philippe Armand

doi:10.1634/theoncologist.2020-0040

Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

Reid W. Merryman, Nicole A. Carreau, Ranjana H. Advani, Michael A. Spinner, Alex F. Herrera, Robert Chen, Sarah Tomassetti, Radhakrishnan Ramchandren, Muhammad Hamid, Sarit Assouline, Raoul Santiago, Nina Wagner-Johnston, Suman Paul, Jakub Svoboda, Steven M. Bair, Stefan K. Barta, Yang Liu, Sunita Nathan, Reem Karmali, Madelyn BurkartPallawi Torka, Kevin A. David, Catherine Wei, Frederick Lansigan, Lukas Emery, Daniel Persky, Sonali M. Smith, James Godfrey, Julio Chavez, Jonathan B. Cohen, Andrea B. Troxel, Catherine Diefenbach, Philippe Armand

School of Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p =.035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p =.003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.

Original language	English (US)
Pages (from-to)	e993-e997
Journal	Oncologist
Volume	25
Issue number	6
DOIs	https://doi.org/10.1634/theoncologist.2020-0040
State	Published - Jun 1 2020

ASJC Scopus subject areas

General Medicine

Access to Document

10.1634/theoncologist.2020-0040

Cite this

Merryman, R. W., Carreau, N. A., Advani, R. H., Spinner, M. A., Herrera, A. F., Chen, R., Tomassetti, S., Ramchandren, R., Hamid, M., Assouline, S., Santiago, R., Wagner-Johnston, N., Paul, S., Svoboda, J., Bair, S. M., Barta, S. K., Liu, Y., Nathan, S., Karmali, R., ... Armand, P. (2020). Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist, 25(6), e993-e997. https://doi.org/10.1634/theoncologist.2020-0040

Merryman, RW, Carreau, NA, Advani, RH, Spinner, MA, Herrera, AF, Chen, R, Tomassetti, S, Ramchandren, R, Hamid, M, Assouline, S, Santiago, R, Wagner-Johnston, N , Paul, S, Svoboda, J, Bair, SM, Barta, SK, Liu, Y, Nathan, S, Karmali, R, Burkart, M, Torka, P, David, KA, Wei, C, Lansigan, F, Emery, L, Persky, D, Smith, SM, Godfrey, J, Chavez, J, Cohen, JB, Troxel, AB, Diefenbach, C & Armand, P 2020, 'Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma', Oncologist, vol. 25, no. 6, pp. e993-e997. https://doi.org/10.1634/theoncologist.2020-0040

@article{3853f84a0ebd48fcb4d8ed475e6ac2eb,

title = "Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma",

abstract = "Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p =.035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p =.003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.",

author = "Merryman, {Reid W.} and Carreau, {Nicole A.} and Advani, {Ranjana H.} and Spinner, {Michael A.} and Herrera, {Alex F.} and Robert Chen and Sarah Tomassetti and Radhakrishnan Ramchandren and Muhammad Hamid and Sarit Assouline and Raoul Santiago and Nina Wagner-Johnston and Suman Paul and Jakub Svoboda and Bair, {Steven M.} and Barta, {Stefan K.} and Yang Liu and Sunita Nathan and Reem Karmali and Madelyn Burkart and Pallawi Torka and David, {Kevin A.} and Catherine Wei and Frederick Lansigan and Lukas Emery and Daniel Persky and Smith, {Sonali M.} and James Godfrey and Julio Chavez and Cohen, {Jonathan B.} and Troxel, {Andrea B.} and Catherine Diefenbach and Philippe Armand",

note = "Publisher Copyright: {\textcopyright} AlphaMed Press 2020",

year = "2020",

month = jun,

day = "1",

doi = "10.1634/theoncologist.2020-0040",

language = "English (US)",

volume = "25",

pages = "e993--e997",

journal = "Oncologist",

issn = "1083-7159",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

AU - Merryman, Reid W.

AU - Carreau, Nicole A.

AU - Advani, Ranjana H.

AU - Spinner, Michael A.

AU - Herrera, Alex F.

AU - Chen, Robert

AU - Tomassetti, Sarah

AU - Ramchandren, Radhakrishnan

AU - Hamid, Muhammad

AU - Assouline, Sarit

AU - Santiago, Raoul

AU - Wagner-Johnston, Nina

AU - Paul, Suman

AU - Svoboda, Jakub

AU - Bair, Steven M.

AU - Barta, Stefan K.

AU - Liu, Yang

AU - Nathan, Sunita

AU - Karmali, Reem

AU - Burkart, Madelyn

AU - Torka, Pallawi

AU - David, Kevin A.

AU - Wei, Catherine

AU - Lansigan, Frederick

AU - Emery, Lukas

AU - Persky, Daniel

AU - Smith, Sonali M.

AU - Godfrey, James

AU - Chavez, Julio

AU - Cohen, Jonathan B.

AU - Troxel, Andrea B.

AU - Diefenbach, Catherine

AU - Armand, Philippe

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p =.035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p =.003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.

AB - Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p =.035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p =.003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.

UR - http://www.scopus.com/inward/record.url?scp=85084224293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084224293&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2020-0040

DO - 10.1634/theoncologist.2020-0040

M3 - Article

C2 - 32275786

AN - SCOPUS:85084224293

SN - 1083-7159

VL - 25

SP - e993-e997

JO - Oncologist

JF - Oncologist

IS - 6

ER -

Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this